PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy

NCT01696565 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm Metastasis
Neoplasm Recurrence

Interventions

DRUG: PG2

Sponsor

PhytoHealth Corporation